Cipla Ltd. reported a decline in consolidated profitability for the quarter ended March 31, 2026, as operating margins weakened amid higher expenses.
Revenue from operations during Q4 FY26 stood at ₹6,541.20 crore compared to ₹6,729.69 crore in the corresponding quarter last year.
The pharmaceutical company posted a consolidated net profit of ₹542.51 crore for the March quarter, down sharply from ₹1,214.14 crore reported in Q4 FY25.
At the operating level, EBITDA stood at ₹954.95 crore in Q4 FY26 compared to ₹1,537.59 crore in the year-ago period, reflecting a decline of nearly 37.9% YoY. EBITDA margin contracted to 14.60% from 22.85% in Q4 FY25.
Profit before tax and share of profit/loss from associates stood at ₹707.06 crore for the quarter against ₹1,504.30 crore in the corresponding quarter previous year.
Total expenses increased to ₹5,982.30 crore during the quarter compared to ₹5,514.85 crore in Q4 FY25. Employee benefit expenses rose to ₹1,414.25 crore from ₹1,233.10 crore, while other expenses stood at ₹1,881.30 crore against ₹1,769.98 crore a year ago.
Depreciation, impairment and amortisation expense during the quarter came in at ₹382.92 crore compared to ₹308.73 crore in the year-ago period.
Earnings per share (EPS) for the quarter stood at ₹6.87 compared to ₹15.13 in Q4 FY25.
The company reported total comprehensive income of ₹678.30 crore for the March quarter against ₹1,268.60 crore in the corresponding quarter last year.
Cipla is among India’s leading pharmaceutical companies with operations across respiratory, anti-infective, cardiology and chronic therapy segments, along with a growing global footprint.